Biogen Says Aduhelm Significantly Lowers Another Top Alzheimer's Biomarker

Despite the controversy surrounding the approval of Biogen’s Alzheimer’s drug Aduhelm (aducanumab), the company announced new data that shows the medication reduces amyloid plaque and significantly lowers plasma p-tau181, a biomarker of the hallmark tau tangles in Alzheimer’s disease.